Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin

International Journal of Oncology

Volumn 10, Issue 5, 1997, Pages 877-884

  Jungwirth, Andreas ^a,c   Schally, Andrew V ^a,b   Nagy, Attila ^a   Pinski, Jacek ^a   Groot, Kate ^a   Galvan, Georg ^a   Szepeshazi, Karoly ^a   Halmos, Gabor ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c St Johanns Spital   (Austria)

Author keywords

2 pyrrolinodoxorubicin; Dunning tumor; LH RH; prostate carcinoma; targeted chemotherapy

Indexed keywords

2 PYRROLINODOXORUBICIN; DOXORUBICIN DERIVATIVE; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE]; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; TUMOR REGRESSION;

EID: 0030961688     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.5.877     Document Type: Article

References (16)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 65: 5-27, 1996.
2. Schroeder FH and Boyle P: Screening of prostate cancer-necessity or nonsense? Eur J Cancer 29A: 656-661, 1993.
3. Raghavan D: Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15: 371-389, 1988.
4. Rangel C, Matzkin H and Soloway MS: Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 39: 577-582, 1992.
5. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P, Miyazaki M, Comaru-Schally AM, Yano T and Emons G: LH-RH analogs with cytotoxic radicals. In: Treatment with GnRH Analogs: Controversies and Perspectives. Filicori M and Flamigni C (eds). Carnforth, Parthenon, pp33-44, 1996.
6. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hoelzel F, Schulz KD and Serially AV: High affinity binding and direct antiproliferative effects of LH-RH analogues in human ovarian cancer cell lines. Cancer Res 53: 5446-5459, 1993.
7. Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K and Nagy A: Effect of cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlation between growth characteristics and EGF receptor content of tumors. Breast Cancer Res Treat 40: 129-139, 1996.
8. Steel RGD and Torrie J: Principles and procedures of statistics. McGraw Hill, New York, pp114, 1976.
9. Schally AV, Kook AI, Monje E, Redding TW and Paz-Bouza JI: Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model. Proc Natl Acad Sci USA 83: 8764-8768, 1986.
10. Isaacs JT: Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 49: 6290-6294, 1989.
11. Limonta J, Dondi D, Moretti RM, Maggi R and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212, 1992.
12. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54: 4091-4095, 1994.
13. Samaan NA, De Asis DN, Buzdar AU and Blumenschein GR: Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 41: 2084-2087, 1978.
14. Sherwood ER and Lee C: Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 15: 290-296, 1995.
15. Milovanovic SR, Monje E, Szepeshazi K, Radulovic S and Schally AV: Effect of treatment with LH-RH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing hormone-releasing hormone in MXT mouse mammary carcinoma. J Cancer Res Clin Oncol 119: 273-278, 1993.
16. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai R-Z, Groot K and Schally AV: LH-RH antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate (In press).